ANNUAL REPORT FY23 27 Relationship between the remuneration policy and Consolidated Entity performance The Board considers that at this time, evaluation of the Consolidated Entities financial performance using generally accepted measures such as profitability, total shareholder return or benchmarking are not relevant as the Consolidated Entity is in the pre-clinical phase of drug development. 1 Resigned as non-executive director on 1 August 2022. 2 Appointed as non-executive director on 1 August 2022. 3 The value included in the share-based payment options column is calculated using sophisticated financial models. The expense is apportioned from the grant date to the date the options vest. As at the date of this report no KMP options have been exercised and this amount does not represent a cash benefit to the key management personnel. 2023 Short-term employee benefits Postemployment benefits Share-based payments Total Salary & fees Bonus Other Superannuation Options and performance shares3 $ $ $ $ $ $ Non-Executive Directors John Moore 193,342 - - - 21,698 215,040 Peter Marks1 20,221 - - - 10,849 31,070 Rüdiger Weseloh1 74,362 - - - 10,849 85,211 Marcus Frampton 81,798 - - - 10,849 92,647 Christopher Cox 81,798 - - - 10,849 92,647 Ian Dixon 89,798 - - - 135,333 225,131 Gisela Mautner2 63,563 - - 4,704 68,267 Executive Employees James Bonnar (CEO) 294,178 - 27,261 27,500 45,120 394,059 Total 899,060 - 27,261 32,204 245,547 1,204,072 2022 Short-term employee benefits Postemployment benefits Share-based payments Total Salary & fees Bonus Other Superannuation Options and performance shares2 $ $ $ $ $ $ Non-Executive Directors John Moore 181,135 - - - 83,698 264,833 Peter Marks 76,275 - - - 41,849 118,124 Rüdiger Weseloh1 82,812 - - - 41,849 124,661 Marcus Frampton 76,633 - - - 41,849 118,482 Christopher Cox 76,633 - - - 41,849 118,482 Ian Dixon 76,577 - - - 177,275 253,852 Executive Employees James Bonnar (CEO) 273,750 - 21,093 27,375 141,928 464,146 Total 843,815 - 21,093 27,375 570,297 1,462,580
RkJQdWJsaXNoZXIy MjE2NDg3